Germline BLM mutations and metastatic prostate cancer.
Elisa M LedetEmmanuel S AntonarakisWilliam B IsaacsTamara L LotanColin PritchardA Oliver SartorPublished in: The Prostate (2019)
Truncating BLM germline mutations occur at a higher frequency in patients with advanced prostate cancer as compared to control populations. Though no biallelic loss of BLM was no noted in cancers, a surprising number of the BLM germline heterozygotes had pathogenic BRCA2 mutations in their tumor.